Related Experiment Video

Updated: Sep 28, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.1K

Therapeutic targeting of TANK-binding kinase signaling towards anticancer drug development: Challenges and

Manzar Alam1, Md Meraj Ansari2, Saba Noor1

  • 1Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi 110025, India.

International Journal of Biological Macromolecules
|March 31, 2022
PubMed

Insights

TANK-binding kinase 1 (TBK1) is crucial for cellular signaling and implicated in cancer. Targeting TBK1 with specific inhibitors shows promise for developing novel anti-cancer therapies.

Area of Science:

  • Molecular Biology
  • Cellular Signaling
  • Oncology

Background:

  • TANK-binding kinase 1 (TBK1) is a key regulator of inflammatory, interferon, NF-κB, autophagy, and Akt signaling pathways.
  • Post-translational modifications (PTMs) of TBK1 critically influence its activity and downstream cellular responses.
  • Dysregulation of the TBK1 pathway is linked to various pathophysiological conditions, notably cancer.

Purpose of the Study:

  • To review current knowledge on the molecular mechanisms of TBK1.
  • To explore the role of TBK1 in cancer development and progression.
  • To highlight the therapeutic potential of TBK1 inhibitors in cancer treatment.

Main Methods:

  • Literature review of studies on TBK1 molecular mechanisms and cancer-related roles.
  • Analysis of pre-clinical data on TBK1 targeting strategies.
  • Compilation of information on existing potent and selective TBK1 inhibitors.

Main Results:

  • TBK1's fundamental role in diverse cellular signaling cascades is confirmed.
  • Evidence suggests TBK1 pathway dysregulation contributes to oncogenesis.
  • Pre-clinical models indicate TBK1 inhibition as a viable anti-tumor strategy.

Conclusions:

  • Targeting TBK1 presents a promising therapeutic avenue for cancer treatment.
  • Specific TBK1 inhibitors, including Amlexanox and BX795, demonstrate potential for anti-cancer therapy.
  • Further research into TBK1 inhibitors could lead to new treatments for cancer and TBK1-associated diseases.
Keywords:
Anti-inflammatoryCellular signalingKinase inhibitorsTANK-binding kinase 1TBK1 inhibitorsTargeted therapy

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K